| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	HC Wainwright & Co. analyst Yi Chen reiterates Edesa Biotech (NASDAQ:EDSA) with a Buy and maintains $5 price target.
																	
																	
																	
																	Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics ...
																	
																	
																	Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29)...
																	-SEC Filing